GlassScriptPhysician profile
Lisa Marie Shoemaker
NPI 1922621762
$2,088.96
in general payments reported to CMS, 2019-2025
37 companies · $609 in 2025
The $609 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.95 · 2023: $425 · 2024: $1,037 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.71 | 2023-2025 | |
| Novo Nordisk INC | $228.36 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $149.99 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $133.86 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Medtronic, INC. | $80.61 | 2024 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $63.49 | 2023-2024 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $63.37 | 2024 | Dupixent |
| Astellas Pharma US INC | $55.72 | 2024-2025 | Veozah |
| Antares Pharma, INC. | $52.30 | 2024-2025 | Xyosted |
| Dexcom, INC. | $51.88 | 2023-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $47.24 | 2024-2025 | Eliquis, Cobenfy |
| Novartis Pharmaceuticals Corporation | $45.27 | 2023-2024 | |
| Lilly USA, LLC | $42.98 | 2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $40.99 | 2023-2024 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $39.29 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.